Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $8.60.

A number of research analysts have recently commented on the company. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock worth $338,591 over the last three months. 12.90% of the stock is owned by insiders.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. increased its stake in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after purchasing an additional 450,949 shares during the period. State Street Corp increased its stake in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after purchasing an additional 677,024 shares during the period. Renaissance Technologies LLC increased its stake in Ironwood Pharmaceuticals by 5.5% in the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after purchasing an additional 469,043 shares during the period. Geode Capital Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock valued at $14,652,000 after acquiring an additional 13,028 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock valued at $8,786,000 after acquiring an additional 78,969 shares in the last quarter.

Ironwood Pharmaceuticals Price Performance

IRWD stock opened at $1.41 on Monday. Ironwood Pharmaceuticals has a 1-year low of $1.34 and a 1-year high of $9.01. The company has a market capitalization of $225.64 million, a price-to-earnings ratio of -47.00 and a beta of 0.37. The business has a 50 day simple moving average of $2.27 and a two-hundred day simple moving average of $3.48.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.